Amicus Therapeutics Gross Profit | FOLD

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:

Raw materials and supplies

Wages of production personnel

Depreciation of equipment

Transportation and warehousing costs (if directly related to production)

Importance for business:

Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales.
Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit.
Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry.
Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.

Reasons for a decline in gross profit:

Increase in raw material and supply costs
Rising production expenses
Price reductions due to competition
Decrease in sales volume
Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Amicus Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002
561 M	475 M	362 M	291 M	271 M	230 M	160 M	76.8 M	30.7 M	4.12 M	-	-	363 K	-	21.4 M	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
561 M	363 K	207 M

Quarterly Gross Profit Amicus Therapeutics

2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
21.5 M	128 M	115 M	96.8 M	-	128 M	115 M	96.8 M	-	93.6 M	85.4 M	79.3 M	-	68.3 M	72.5 M	71.1 M	-	67.8 M	69 M	59.9 M	-	59 M	55.7 M	54 M	-	43.2 M	38.8 M	30 M	-	16.3 M	18.2 M	14.1 M	-	9.08 M	6.1 M	3.39 M	-	1.78 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
128 M	1.78 M	59.3 M

Gross Profit of other stocks in the Biotechnology industry

Issuer	Gross Profit	Price	% 24h	Market Cap	Country
Институт стволовых клеток человека ISKJ	774 M	-	-	-	Russia
Завод ДИОД DIOD	325 M	-	-	-	Russia
Фармсинтез LIFE	160 M	-	-	-	Russia
Ionis Pharmaceuticals IONS	1.12 B	$ 43.5	0.62 %	$ 6.96 B	USA
Agios Pharmaceuticals AGIO	117 M	$ 31.25	0.88 %	$ 1.81 B	USA
Inhibikase Therapeutics IKT	698 K	$ 2.0	0.5 %	$ 197 M	USA
Kamada Ltd. KMDA	76.4 M	$ 8.0	1.34 %	$ 461 M	Israel
Ultragenyx Pharmaceutical RARE	265 M	$ 14.5	3.19 %	$ 1.43 B	USA
Viridian Therapeutics VRDN	1.05 K	$ 19.0	2.16 %	$ 1.93 B	USA
AbbVie ABBV	12.1 B	$ 265.76	1.12 %	$ 470 B	USA
Abeona Therapeutics ABEO	925 K	$ 5.11	1.59 %	$ 271 M	USA
Arbutus Biopharma Corporation ABUS	-40.6 M	$ 4.67	4.94 %	$ 895 M	Canada
ACADIA Pharmaceuticals ACAD	473 M	$ 20.11	0.8 %	$ 3.39 B	USA
Achieve Life Sciences ACHV	18.2 M	$ 7.01	0.13 %	$ 306 M	USA
Aclaris Therapeutics ACRS	172 K	$ 4.27	0.79 %	$ 523 M	USA
ADMA Biologics ADMA	293 M	$ 10.11	4.01 %	$ 2.41 B	USA
Adaptive Biotechnologies Corporation ADPT	62.8 M	$ 29.84	5.26 %	$ 4.53 B	USA
Agenus AGEN	-18.3 M	$ 8.73	4.43 %	$ 260 M	USA
AIM ImmunoTech AIM	-643 K	$ 0.19	5.56 %	$ 308 K	USA
Akebia Therapeutics AKBA	190 M	$ 0.91	5.26 %	$ 234 M	USA
Aligos Therapeutics ALGS	-10.5 M	$ 5.4	0.36 %	$ 53.4 M	USA
Alkermes plc ALKS	991 M	$ 42.76	2.42 %	$ 7.04 B	Irlanda
Alnylam Pharmaceuticals ALNY	195 M	$ 219.89	0.08 %	$ 28.8 B	USA
Altimmune ALT	8.18 K	$ 2.67	0.36 %	$ 235 M	USA
ALX Oncology Holdings ALXO	436 K	$ 1.21	1.23 %	$ 64.9 M	USA
Amgen AMGN	19 B	$ 402.98	0.08 %	$ 217 B	USA
Amphastar Pharmaceuticals AMPH	356 M	$ 25.37	0.39 %	$ 1.19 B	USA
Amarin Corporation plc AMRN	121 M	$ 12.09	0.31 %	$ 5.02 B	Irlanda
Amneal Pharmaceuticals AMRX	1.11 B	$ 20.35	0.25 %	$ 6.38 B	USA
Anika Therapeutics ANIK	63.8 M	$ 19.73	3.3 %	$ 283 M	USA
ANI Pharmaceuticals ANIP	143 M	$ 72.58	0.55 %	$ 1.46 B	USA